Medtronic (MDT) Reports In-Line Q2 EPS; Updates on FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Medtronic (MDT) PT Raised to $83 at Piper Jaffray Following Q2 and Deal Progress
November 19, 2014 8:45 AM ESTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Medtronic, Inc. (NYSE: MDT) to $83.00 (from $74.00) Wednesday following solid Q2 results and progress on the Covidien deal.
West commented, "
Medtronic reported F2Q15 results with revenues of $4.366B... More
